Long-term outcome after neo-adjuvant chemotherapy for breast cancer in BRCA1/2 carriers

International Journal of Cancer

Volumn 125, Issue 9, 2009, Pages 2236-2238

  Keet, Annick Wong Wong ^a   Al Rafae, Munir ^a   Chappuis, Pierre O ^b   Brunet, Jean Sébastien ^a,c   Ghadirian, Parviz ^d   Foulkes, William D ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c PHARSIGHT CORPORATION   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER SURVIVAL; GENE IDENTIFICATION; GENE MUTATION; HETEROZYGOTE; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME; ADULT; AGED; BREAST TUMOR; CHEMISTRY; FEMALE; GENETICS; MIDDLE AGED; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; MIDDLE AGED; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 70249104279     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24596     Document Type: Letter

References (12)

1. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006;5:135-142
2. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002;39:608-610 (Pubitemid 34864568)
3. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Begin LR, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029-2034 (Pubitemid 38375563)
4. Herold CI, Marcom PK. Primary systemic therapy in breast cancer: past lessons and new approaches. Cancer Invest 2008;26:1052-1059
5. Hubert A, Mali B, Hamburger T, Rottenberg Y, Uziely B, Peretz T, Kadouri L. Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer. Fam Cancer, Published on-line November 19, 2008; DOI: 10.1007/s10689-008-9223-7.
6. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Narod SA, Lubinski J. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008;108:289-296 (Pubitemid 351311366)
7. Warner E, Trudeau M, Holloway C. Sensitivity of BRCA-1-related breast cancer to neoadjuvant chemotherapy: practical implications. Breast J 2003;9:507-508 (Pubitemid 37433221)
8. Melichar B, Fridrichova P, Lukesova S, Mergancova J, Urminska H, Ryska A, Foretova L. Pathological complete response after primary chemotherapy in a mother and daughter with hereditary breast carcinoma: two case reports. Eur J Gynaecol Oncol 2008;29:188-190
9. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Begin LR, Offit K, Foulkes WD. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004;6:R8-R17.
10. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:115-123 (Pubitemid 47057729)
11. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, Kladny J, Gorski B, Lubinski J, Narod SA. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat, Published on-line July 23 2008; DOI: 10.1007/s10549-008-0128-9.
12. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-676